Neurología

A continuación se enumeran ensayos clínicos actuales.

Filtrar esta lista de estudios según la ubicación, el estado del estudio y más.

1. Investigation of Regulatory Genes in Pathophysiology of Craniosynostosis

   Rochester, Minn.

   The purpose of this study is to collect tissue (during the initial procedure only) that is surgically removed (and routinely discarded at Mayo Clinic) from CS patients. Portions of the tissue will be embedded in plastic for histological and histomorphometric analysis. A small portion of the tissue will be used for outgrowth cultures to isolate cells. Nucleic acid and protein will be extracted from the remaining portions of the tissue and/or isolated cell lines to examine candidate genes and their role in the disease process.

2. A Study of Congenital Myasthenic Syndromes

   Rochester, Minn.

   The proposed studies are important for diagnosis and prevention of congenital myasthenic syndromes (CMS), for investigating disease pathophysiology, for developing strategies for therapy, and for gaining insights into structure-function relationships of EP-specific proteins.

3. Collection and Storage of DNA and Plasma in Patients with Dysautonomia and Healthy Controls

   Rochester, Minn.

   This study is being done to better understand the causes of autonomic disorders, and to collect and store DNA and plasma for future studies of autonomic disorders.

4. A Study of Neurophysiological and Inflammatory Biomarkers of Seizures and Brain Injury in Children

   Rochester, Minn.

   The purpose of this study is to connect brain inflammation measured by biomarkers, with data from advanced EEG technology, and clinical outcomes to provide new predictive information about seizure activity in children with critical brain injuries and epilepsy.

5. A Study of Atrial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

   Jacksonville, Fla.

   The primary purpose of this study is to test the theory that Eliquis (apixaban) is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.

6. Natural History Study Protocol in PMM2-CDG (CDG-Ia)

   Rochester, Minn.

   Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P.

7. A Study to Test the Effectiveness and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects with Drug-resistant Epilepsy

   Rochester, Minn.

   The purpose of the study is to evaluate the effectiveness, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered simultaneously with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in adult subjects with drug-resistant epilepsy.

8. Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure

   Rochester, Minn.

   The study is a prospective, multi-center, non-randomized, open label observational study. The objective of this study is to compare the accuracy of the EyeBOX to a clinical diagnosis of abnormal ICP as determined by an external ventriculostomy drain (EVD) or ventriculostomy catheter.

9. A Study of Mood Symptoms in Epilepsy Patients

   Rochester, Minn.

   The purpose of this study is to track neuropsychiatric symptoms in patients with epilepsy.

10. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients

    Rochester, Minn.

    The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: